EDAP Ablatherm-HIFU Presentations Receive "Best Poster" Awards at the 27th Annual European Association of Urology Congress

Comprehensive Data Supports Prostate Cancer Control Utilizing Ablatherm(R)-HIFU

LYON, France, Feb. 24, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced today that Ablatherm® High Intensity Focused Ultrasound (HIFU) will be featured in seven poster presentations supporting the technology's efficacy for the treatment of localized prostate cancer, and two of these presentations have been awarded "Best Posters" highlighting HIFU clinical data relevance. Ablatherm-HIFU and the Company's renewed lithotripsy Sonolith product range will be showcased at the 27th Annual European Association of Urology (EAU) Congress, which will be held on February 24 — 28 in Paris, France.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We are particularly pleased that two of our Ablatherm-HIFU posters have been selected as 'Best Posters' by the European Urology Association. This confirms the recognition and acceptance of HIFU as one of the hottest topic in modern urology. It validates the support from the international urology community for Ablatherm-HIFU's positioning as a complement to surgery in addressing prostate cancer and proven ability to bring minimally invasive treatment to patients and urologists."

The data presented by some of the most experienced and long term HIFU leaders fully supports utilizing Ablatherm-HIFU device to precisely control prostate cancer disease as compared to more radical treatment options. It allows for a targeted nerve-sparing approach with reduced side effects and greater preservation of quality of life. The treatment paradigm for localized prostate cancer management is a minimally-invasive approach designed to only target cancer cells.

The EAU presentations outline Ablatherm-HIFU as a valid treatment option for all potential prostate cancer stages ranging from low risk cancers (T1-T2) to more advanced high risk cancers (T3 — T4). The favorable long term data also supports HIFU efficacy in the treatment of radiotherapy failures when no other alternative is offered. Poster findings report long term multi-center clinical results based on a large series of patients treated with Ablatherm-HIFU.

Mr. Oczachowski concluded, "We are continuing to build our clinical experience as demonstrated by the ongoing expansion of our comprehensive @-REGISTRY Ablatherm-HIFU patient database that supports clinical analysis and publications. We will continue to work closely with renowned urologists and surgeons to advance Ablatherm-HIFU option as the complement to surgery to further control prostate cancer."

Scientific Session Highlights on Ablatherm-HIFU experiences and outcomes

Date/Time: Saturday, February 25 / 8:30 am

Poster Session 2: Focal therapy: what is new and improved?

Poster #17: Morbidity of focal therapy in the treatment of localized prostate cancer

Date/Time: Sunday, February 26 / 12:00 pm to 2:00 pm

ESU Course: Minimally invasive prostate cancer therapy:

HIFU Therapy — Update 2012: why TUR before?

Focal HIFU — no TUR, outlook to the future?

Date/Time: Monday, February 27 / 12:15 pm

Poster Session 74: Prostate cancer: Prognosis

Poster #888: Robotic high intensity ultrasound at 3 MHz delays onset of androgen deprivation therapy in locally advanced prostate cancer

Date/Time: Monday, February 27 / 2:00 pm

Poster #978: Robotic high intensity focused ultrasound at 3 MHz in localized prostate cancer: Side effects of 704 patients within 10 years

Poster #979: Localized prostate cancer control with primary HIFU therapy: Outcomes from 5663 men followed with the @-Registry

Poster #980: Oncological outcomes of high-intensity focused ultrasound for localized prostate cancer in 1098 consecutive patients

Poster #981: Survival analysis of patients following prostate cancer treatment with high intensity focused ultrasound (HIFU) during a treatment period of 13 years

Poster #982: Multicentric oncologic outcomes of salvage HIFU for local failure after external beam radiotherapy: 7 years biochemical survival of 929 patients.

The Company will be exhibiting Ablatherm-HIFU and its renewed lithotripsy product range Sonolith i-sys and i-move at its EAU booth # 2M65.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm®, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit *http://www.edap-tms.com, and http://www.hifu-planet.com.*

CONTACT: Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 72

bconfort@edap-tms.com

Investors:

Stephanie Carrington

The Ruth Group

646-536-7017

scarrington@theruthgroup.com

Source: EDAP TMS SA